N/A N=60 Hemodynamic Comparison of Tissue Aortic Valves
Aortic Valve Stenosis
Primary: Aortic Valve Mean Gradient (mm Hg) at Peak Exercise — 11; 14; 11 mm Hg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=88 Behavior of Valve Leaflets Following Aortic Valve Implant
Aortic-valve Replacement
Primary: Reduction in Leaflet Motion — 12 Participants
Phase 2 N=23 A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
Aortic Valve Stenosis
Primary: Changes in Aortic Valve Calcium Levels — 65; 215 Arbitrary Units — p=0.05
N/A N=756 Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve
Heart Valve Diseases
Primary: Incidence Rate of Adverse Events and Mortality for the Mitroflow Aortic Heart Valve Repair — 7.1; 1.27; 0.21; 0.56 Percent occurrence per patient-year
N/A N=934 Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
Aortic Valve Stenosis · Aortic Valve Stenosis With Insufficiency · Regurgitation, Aortic Valve
Primary: Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage) for the INTUTY Valve Implanted Cohort — 3.9; 0.9; 0.6; 0.3 Percentage of…
N/A N=55 Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic Stenosis
Aortic Valve Stenosis
Primary: Composite Success of Improvement in New York Heart Association (NYHA) Class and a Performance Goal for Effective Orifice Area (EOA). — 93.6; 91.7 percentage of…
N/A N=20 Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis
Aortic Valve Stenosis
Primary: Composite Score of Change in New York Heart Association (NYHA) Class and Effective Orifice Area (EOA). — 75.0; 87.5 percentage of participants analyzed — p=0.002
N/A N=90 Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves
Eisenmenger Syndrome
Primary: Number of Participants Who Developed Infective Endocarditis — 9 participants
N/A N=295 Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve
Aortic Valve Stenosis With Insufficiency · Aortic Valve Stenosis
Primary: Percent of Early Adverse Events — 1.7; 1.0; 4.5; 0.0 Percentage of subjects
N/A N=1,022 Aortic Valve Replacement With Trifecta(TM)
Aortic Valve Insufficiency · Regurgitation, Aortic Valve · Aortic Valve Incompetence
Primary: Late Adverse Event Rates — 1.90; 0; 2.61; 0.12 percentage of events/late patient years
N/A N=30 Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation
Native and Valve in Valve Aortic Valve Failure
Primary: Number of Participants With Procedure Success, Measured at Exit From the Catheterization Laboratory — 28 participants
N/A N=64 Study of Aortic Root Reimplantation Procedure
Ascending Aortic Aneurism · Aortic Valve Insufficiency
Primary: Freedom From Aortic Insufficiency More Than 2+ (Percentage, Kaplan-Meier) — 88.2; 87.7 percentage of participants
N/A N=50 Correlation of Auscultatory Severity of Aortic Stenosis With Trans Thoracic Echocardiography
Aortic Stenosis
Primary: Aortic Stenosis Acceleration Index Compared to Aortic Stenosis Severity — 21; 8; 1; 6 participants
N/A N=100 ADVANCE Direct Aortic Study
Aortic Stenosis · Valvular Heart Disease
Primary: All-cause Mortality — 4.4 Percentage of subjects
N/A N=37 DEFLECT I: Keystone Heart Embolic Deflection Trial
Aortic Stenosis
Primary: Number of Patients Where the Device Accessed, Deployed and Was Positioned in the Aortic Arch (Device Performance) — 33 Participants
N/A N=297 Aortic or Mitral Valve Replacement With the Biocor and Biocor Supra
Aortic Valve Insufficiency · Aortic Valve Regurgitation · Aortic Valve Stenosis
Primary: Number of Participants With Adverse Events — 6; 14; 53; 10 participants
N/A N=50 Study to Evaluate the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections
Aortic Dissection
Primary: All Cause Mortality. — 4 participants
N/A N=634 CoreValve® System Australia/New Zealand Clinical Study
Aortic Valve Stenosis
Primary: Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) Rate — 0.099 probability of events at 30 days
N/A N=120 EDWARDS INTUITY Valve System CADENCE Study
Aortic Valve Disease · Aortic Stenosis
Primary: Average Subject Time Spent on Cardiopulmonary Cross Clamp — 77.5; 82.0 Minutes — p=0.3660
N/A N=116 COronary and MICrocirculatory Measurements in Patients With Aortic Valve Stenosis.
Aortic Stenosis · Coronary Artery Disease
Primary: FFR 6 Months After SAVR/TAVI. — -0.0279 ratio
N/A N=126 Clinical Evaluation of Percutaneous Implantation of the Medtronic CoreValve Aortic Valve Prosthesis (18Fr-Study)
Aortic Valve Stenosis
Primary: Composite Major Adverse Event (MAE) Free Rate — 54.2; 48.1; 51.6 Percentage of subjects
N/A N=100 EDWARDS INTUITY Valve System CADENCE-MIS Study
Aortic Valve Disease · Aortic Stenosis
Primary: Median Subject Time Spent on Cardiopulmonary Cross Clamp — 35.0; 47.5 Minutes — p=<0.0001
N/A N=16 HAART Model 300 Annuloplasty Ring
Aortic Regurgitation
Primary: Primary Safety Outcome Measure: Event-free Survival — 100 percentage of participants
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Phase 3 N=1,873 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)
Aortic Stenosis
Primary: Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events) — 333; 355 Participants — p=0.591
Phase 2 N=251 Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 54.6; 60.7 ml per square meter of body-surface area — p=0.18
Phase 3 N=231 Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Aortic Valve Stenosis · Cardiovascular Diseases · Heart Valve Diseases
Primary: Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan — 11; 2 Participants — p=0.01
N/A N=20 Engager Direct Aortic Clinical Study
Aortic Valve Stenosis
Primary: Acute Delivery System Success — 95.0 percentage of participants
N/A N=283 Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX
Coronary Artery Disease · Aortic Valve Disorder · Heart Failure
Primary: Subject's Percentage of Long Term Safety Performance — 1.5; 2.7; 0.2; 0.4 Percentage of events/late patient years
N/A N=64 Assessment of the St Jude Medical Portico Resheathable Aortic Valve System-Alternative Access
Aortic Valve Stenosis
Primary: Number of Participants With Major Vascular Complications — 2; 1 Participants